Qiagen (QGEN)

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.

Company profile

Ticker

QGEN

Exchange

NYSE

Website

www.qiagen.com

CEO

Thierry Bernard

Incorporated

Netherlands

Location

Netherlands

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics • Allogene Therapeutics ...

Former names

QIAGEN NV

SEC CIK

0001015820

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

QGEN stock data

1M 1Y 5Y

News

From Benzinga Pro

QIAGEN Reports Purchase Of Majority Stake In BLIRT, No Terms Disclosed

11 May 22

BLIRT adds new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents Strengthens QIAGEN’s sample technologies business, one of the

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

6 May 22

QIAGEN Continues To Update Its Range Of Automation Solutions With The Launch Of High-sensitive Capillary Electrophoresis Instrument Qiaxcel Connect

4 May 22

Qiagen N.V. - QIAGEN continues to update its range of automation solutions with the launch of high-sensitive capillary electrophoresis instrument QIAxcel Connect

Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook

27 Apr 22

Earnings Scheduled For April 27, 2022

27 Apr 22

Press releases

From Benzinga Pro

QIAGEN's Eco-Friendlier Products Earn Prestigious ACT Label

19 May 22

QIAwave products showed 35% lower environmental impact First in industry to receive ACT label for sample preparation kits QIAGEN and My Green Lab to collaborate on laboratory sustainability efforts QIAGEN N.V.

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

16 May 22

QIAstat-Dx Rise, which can process up to 56 tests in an eight-hour shift with enhanced walk-away efficiency, receives CE-marking to run new respiratory and gastrointestinal panels QIAstat-Dx Respiratory SARS-CoV-2

QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.

11 May 22

BLIRT adds new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents Strengthens QIAGEN's sample technologies business, one of the company's

QIAGEN Proposes Expansion of Supervisory Board

11 May 22

QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System

5 May 22

Calendar

14 Mar 22

24 May 22

31 Dec 22

Financial summary

Financial statements Chart QGEN financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Qiagen earnings reports.

Institutional ownership, Q1 2022

QGEN institutional ownership history Ownership history

59.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	285	295	-3.4%
Opened positions	41	61	-32.8%
Closed positions	51	27	+88.9%
Increased positions	102	108	-5.6%
Reduced positions	90	79	+13.9%

13F shares	Current	Prev Q	Change
Total value	6.66B	54.26B	-87.7%
Total shares	134.65M	143.96M	-6.5%
Total puts	244.43K	771.81K	-68.3%
Total calls	1.52M	590.4K	+158.2%
Total put/call ratio	0.2	1.3	-87.7%

Largest owners	Shares	Value	Change
Massachusetts Financial Services	20.51M	$1B	+0.3%
Davidson Kempner Partners	9.61M	$517.39M	0.0%
Vanguard	8.05M	$394.44M	+2.3%
BLK Blackrock	7.24M	$354.53M	-11.6%
Capital World Investors	5.64M	$276.2M	-12.9%
Wellington Management	4.86M	$240.38M	-2.3%
DB Deutsche Bank AG - Registered Shares	4.13M	$202.32M	+20.5%
Davidson Kempner Capital Management	3.5M	$172.43M	-2.0%
Amundi	3.5M	$172.54M	+10.4%
Arrowstreet Capital, Limited Partnership	3.5M	$171.98M	+14.2%

Largest transactions	Shares	Bought/sold	Change
Schroder Investment Management	0	-6.66M	EXIT
Norges Bank	0	-4.81M	EXIT
Citadel Advisors	1.64M	+1.44M	+710.9%
Premier Fund Managers	185.21K	-1.44M	-88.6%
Marshall Wace	1.91M	+1.02M	+114.6%
BLK Blackrock	7.24M	-950.62K	-11.6%
BCS Barclays	1.42M	-925.12K	-39.5%
DekaBank Deutsche Girozentrale	1.49M	-843.89K	-36.1%
Nekton Capital	1.11M	+834.59K	+298.6%
Capital World Investors	5.64M	-832.12K	-12.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Guided Therapeutics • Luminex • Biocept • Exact Sciences • Rosetta Genomics • Veracyte • Nanostring • GenMark Diagnostics • Great Basin Scientific • Lucira Health

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accredited, Actome, ADLT, AGM, ahead, AKS, ambition, amid, amniotic, AmniSure, Ann, appraisal, Arbor, asserted, Atila, attention, Austria, baseline, Bayer, BD, Becton, Bloomberg, breadth, Campaign, capture, carbon, carryback, CCPA, CDPA, CHIP, climate, CMP, Coalition, Collector, Colorado, commodity, compel, complicating, concealing, Congressional, consumption, copy, counter, CPRA, Crimea, debilitating, defect, defrauding, Depositary, devaluation, Dickinson, diminish, discern, disciplined, divert, DOJ, Donetsk, drawn, driver, durability, dysplasia, Ebeling, eighteen, ERP, ERPD, ethnic, fallout, falsifying, Fed, Female, fluid, FN, friendly, geopolitical, globe, gradual, greatly, GT, hacking, Hamburg, ICE, imposition, improperly, inconsistent, incursion, ineffective, instability, interference, Internet, intervene, intervention, invaded, invasion, ISS, jury, justice, legislature, levied, likewise, live, LTI, Luhansk, Lyme, LymeDetect, magnify, mainstream, Male, MDSAP, MDx, mediation, MGH, military, Mirati, Missouri, moderate, Moscow, MSCI, NAV, naval, neonatal, nurse, OFAC, offense, Omicron, OncXerna, onset, PAXgene, persuade, plastic, Plex, population, practitioner, PreAnalytix, preexisting, pressing, proceed, psychology, QIAsphere, QIAwave, quantity, quick, ransomware, recession, recoupment, recyclability, Reg, reintroduced, resumption, ROM, RSV, ruble, Russian, SBTi, score, secret, seizure, separatist, sequester, shrinking, Singular, spun, STI, studio, succeeded, sued, surrendered, syncytial, Sysmex, terrorist, textual, tied, timeframe, tolerance, traction, tranche, trillion, turmoil, Ukraine, UM, unclassified, unfunded, unlawful, unlicensed, upscaling, USA, Vantage, variant, verdict, video, Virginia, war, warfare, warming, wastewater, XETRA, Zone

Removed: administering, administratively, advancing, advertisement, anonymized, ban, barcode, begun, Belgium, Beverly, bipartisan, Brexit, Britain, broadened, burdensome, CA, Cambridge, Centrale, century, claimed, Codevelopment, cole, Commissioner, commit, comparison, contemporary, Coventry, crime, database, deadline, discontinued, EBIT, ECP, Eli, eligibility, Ellume, enzyme, faced, Farmer, favour, finalized, fit, forum, gather, GbR, GINA, GPC, HHS, IBS, IMDRF, Immunodiagnostic, immunological, implicated, Indiana, Ingenium, kickback, Laer, leveraged, Lilly, machinery, Manchester, Manila, marked, messenger, metric, Minden, minimal, Minnesota, MO, modernizing, multiplexing, Munich, Nevada, Nondiscrimination, Nonemployee, nonmarketable, obstacle, occupy, offence, Official, OmicSoft, Operon, outlay, outline, penalty, PLC, Postbank, postmarket, practiced, producer, prohibiting, promise, punishable, putting, QCI, quicker, QVA, read, reclassify, reevaluate, referral, referring, regulating, retrospectively, revalued, RGQ, somatic, sovereign, Stark, steering, stranded, talented, task, technically, territory, throughput, Tokyo, twelve, version, violated, waiver, Wroclaw

From filing 20-F 2021 FY

Financial reports

View all

20-F

2021 FY

Annual report (foreign)

14 Mar 22

20-F

2020 FY

Annual report (foreign)

4 Mar 21

20-F